Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

155 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
From trivalent to quadrivalent influenza vaccines: Public health and economic burden for different immunization strategies in Spain.
Crépey P, Redondo E, Díez-Domingo J, Ortiz de Lejarazu R, Martinón-Torres F, Gil de Miguel Á, López-Belmonte JL, Alvarez FP, Bricout H, Solozabal M. Crépey P, et al. Among authors: ortiz de lejarazu r. PLoS One. 2020 May 21;15(5):e0233526. doi: 10.1371/journal.pone.0233526. eCollection 2020. PLoS One. 2020. PMID: 32437476 Free PMC article.
Influenza vaccine effectiveness in preventing outpatient, inpatient, and severe cases of laboratory-confirmed influenza.
Castilla J, Godoy P, Domínguez A, Martínez-Baz I, Astray J, Martín V, Delgado-Rodríguez M, Baricot M, Soldevila N, Mayoral JM, Quintana JM, Galán JC, Castro A, González-Candelas F, Garín O, Saez M, Tamames S, Pumarola T; CIBERESP Cases and Controls in Influenza Working Group Spain. Castilla J, et al. Clin Infect Dis. 2013 Jul;57(2):167-75. doi: 10.1093/cid/cit194. Epub 2013 Mar 26. Clin Infect Dis. 2013. PMID: 23532475
Cost-effectiveness analysis of quadrivalent influenza vaccine in Spain.
García A, Ortiz de Lejarazu R, Reina J, Callejo D, Cuervo J, Morano Larragueta R. García A, et al. Among authors: ortiz de lejarazu r. Hum Vaccin Immunother. 2016 Sep;12(9):2269-77. doi: 10.1080/21645515.2016.1182275. Epub 2016 May 16. Hum Vaccin Immunother. 2016. PMID: 27184622 Free PMC article.
[Description of Influenza B in seasonal epidemics in Spain].
Ortiz de Lejarazu R, Díez Domingo J, Gil de Miguel A, Martinón Torres F, Guzmán Quilo C, Guillén JM, Piedrafita B, Redondo Marguello E. Ortiz de Lejarazu R, et al. Rev Esp Quimioter. 2018 Dec;31(6):511-519. Epub 2018 Nov 5. Rev Esp Quimioter. 2018. PMID: 30421881 Free PMC article. Spanish.
[High-dose trivalent influenza vaccine. Efficacy and effectiveness].
Gil de Miguel A, Redondo Marguello E, Díez Domingo J, Ortiz de Lejarazu R, Martinón Torres F. Gil de Miguel A, et al. Among authors: ortiz de lejarazu r. Rev Esp Quimioter. 2020 Aug;33(4):226-239. doi: 10.37201/req/043.2020. Epub 2020 Jun 9. Rev Esp Quimioter. 2020. PMID: 32515178 Free PMC article. Review. Spanish.
[High-dose trivalent influenza vaccine: safety and immunogenicity].
Ortiz de Lejarazu R, Martinón Torres F, Gil de Miguel A, Díez Domingo J, Redondo Marguello E. Ortiz de Lejarazu R, et al. Rev Esp Quimioter. 2021 Feb;34(1):1-11. doi: 10.37201/req/110.2020. Epub 2020 Nov 19. Rev Esp Quimioter. 2021. PMID: 33210106 Free PMC article. Review. Spanish.
No Major Host Genetic Risk Factor Contributed to A(H1N1)2009 Influenza Severity.
Garcia-Etxebarria K, Bracho MA, Galán JC, Pumarola T, Castilla J, Ortiz de Lejarazu R, Rodríguez-Dominguez M, Quintela I, Bonet N, Garcia-Garcerà M, Domínguez A, González-Candelas F, Calafell F; CIBERESP Cases and Controls in Pandemic Influenza Working Group. Garcia-Etxebarria K, et al. Among authors: ortiz de lejarazu r. PLoS One. 2015 Sep 17;10(9):e0135983. doi: 10.1371/journal.pone.0135983. eCollection 2015. PLoS One. 2015. PMID: 26379185 Free PMC article.
Group 1 and group 2 hemagglutinin stalk antibody response according to age.
Sánchez-de Prada L, Sanz-Muñoz I, Sun W, Palese P, Ortiz de Lejarazu R, Eiros JM, García-Sastre A, Aydillo T. Sánchez-de Prada L, et al. Among authors: ortiz de lejarazu r. Front Immunol. 2023 May 29;14:1194073. doi: 10.3389/fimmu.2023.1194073. eCollection 2023. Front Immunol. 2023. PMID: 37313413 Free PMC article.
Impact on the time elapsed since SARS-CoV-2 infection, vaccination history, and number of doses, on protection against reinfection.
Sánchez-de Prada L, Martínez-García AM, González-Fernández B, Gutiérrez-Ballesteros J, Rojo-Rello S, Garcinuño-Pérez S, Álvaro-Meca A, Ortiz De Lejarazu R, Sanz-Muñoz I, Eiros JM. Sánchez-de Prada L, et al. Among authors: ortiz de lejarazu r. Sci Rep. 2024 Jan 3;14(1):353. doi: 10.1038/s41598-023-50335-6. Sci Rep. 2024. PMID: 38172152 Free PMC article.
155 results